Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$476K Buy
9,883
+1,026
+12% +$52.4K 0.01% 830
2026
Q2
$464K Buy
8,857
+1,351
+18% +$71.4K 0.01% 824
2026
Q1
$414K Buy
+7,506
New +$407K 0.01% 777
2025
Q4
– Sell
-5,749
Closed -$248K – 417
2025
Q3
$248K Sell
5,749
-238
-4% -$9.3K 0.01% 881
2025
Q2
$230K Buy
+5,987
New +$229K 0.01% 819
2025
Q1
– Sell
-15,604
Closed -$528K – 723
2024
Q4
$528K Buy
+15,604
New +$562K 0.02% 376
2024
Q3
– Sell
-6,999
Closed -$269K – 617
2024
Q2
$269K Sell
6,999
-6,137
-47% -$258K 0.01% 498
2024
Q1
$563K Buy
+13,136
New +$542K 0.02% 325
2014
Q3
– Sell
-4,179
Closed -$279K – 210
2014
Q2
$279K Sell
4,179
-634
-13% -$42.9K 0.06% 145
2014
Q1
$321K Sell
4,813
-442
-8% -$29.9K 0.08% 127
2013
Q4
$351K Buy
+5,255
New +$341K 0.08% 121

Other funds holding GSK

Brighton Jones's GSK Position: Q3 2026 in Review

Brighton Jones increased its GSK (GSK) stake by 12% in Q3 2026, buying an estimated $52.4K and bringing the position to 9,883 shares worth $476K. The position accounts for 0.01% of the portfolio, ranked #830.

Brighton Jones first reported a position in GSK in Q4 2013 and has held it in 11 quarters since. The position peaked at $563K in Q1 2024. 868 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Brighton Jones held 9,883 shares of GSK worth $476K as of Q3 2026.
  • Brighton Jones bought 1,026 GSK shares in Q3 2026, an estimated $52.4K.
  • GSK made up 0.01% of Brighton Jones's portfolio in Q3 2026, its #830 holding.
  • Brighton Jones first reported a position in GSK in Q4 2013 and has held it in 11 quarters since.
  • Brighton Jones's GSK position peaked at $563K in Q1 2024.
  • 868 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.